CervoMed Inc. (CRVO)
CRVO moved a median of 0.00% 30 minutes after news, and -0.18% by the close. How CRVO actually reacts to news — the realized, point-in-time move the market made, measured across 281 labeled events over the last three years with zero look-ahead.
CRVO’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 40% | 259 |
| 30-min | 0.00% | 49% | 274 |
| 60-min | +0.23% | 53% | 275 |
| to close | -0.18% | 47% | 274 |
| Middle 50% of CRVO reactions | -2.38% to +2.40% |
|---|---|
| Median reaction (30-min) | 0.00% |
| Measured reactions | 281 |
Half of all CervoMed Inc. news events land between -2.38% and +2.40% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How CRVO reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 20 | -2.40% | 30% | -2.90% |
| Analyst downgrades | 14 | -1.60% | 7% | -1.88% |
| Coverage initiations | 25 | -0.37% | 40% | -2.47% |
| Rating reiterations | 70 | -0.00% | 46% | -1.90% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 2 further classes were observed with fewer than 10 measured events and are not published. See how CRVO ranks against every other measured name →
That’s how CRVO usually reacts — get an email when it moves on news →Email me when CRVO moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to CRVO's baseline. Nothing else.
Recent CRVO events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 8-K CervoMed Inc. For: Oct 14 | SEC filing · Form 8-K | SEC EDGAR | -1.33% | -0.44% | |
| Form 8-K CervoMed Inc. For: Oct 12 | SEC filing · Form 8-K | SEC EDGAR | -2.48% | -9.20% | |
| CervoMed Presents Initial Results of Phase 2a Trial of Neflamapimod in Nonfluent Variant Primary Progressive Aphasia (nfvPPA) Showing Positive Effects on a Key Neurodegeneration Biomarker in Late-Breaking Oral Session at ISFTD 2026 | Press release | GlobeNewswire | -1.46% | -8.73% | |
| Form 8-K CervoMed Inc. For: Oct 09 | SEC filing · Form 8-K | SEC EDGAR | -1.46% | -8.73% | |
| CervoMed Announces Pharmacokinetic Results with New Neflamapimod Oral Tablet Formulation and Secures FDA Removal of Drug Exposure Limit | Press release | GlobeNewswire | +2.55% | +4.71% | |
| Form 8-K CervoMed Inc. For: Sep 28 | SEC filing · Form 8-K | SEC EDGAR | -0.27% | +6.67% | |
| CervoMed to Participate in the 5th Annual ROTH Healthcare Opportunities Conference | Press release | GlobeNewswire | +0.00% | +4.12% | |
| CervoMed Announces Initial Results from the Phase 2a Clinical Trial of Neflamapimod in Nonfluent Variant Primary Progressive Aphasia (nfvPPA) Have Been Accepted as a Late-Breaking Oral Session at ISFTD 2026 | Press release | GlobeNewswire | +0.00% | -0.80% | |
| Form 8-K CervoMed Inc. For: Sep 10 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +1.18% | |
| CervoMed to Participate in September Investor Conferences | Press release | GlobeNewswire | -2.33% | -1.94% | |
| CervoMed Reports Second Quarter 2026 Financial Results and Provides Corporate Updates | Press release | GlobeNewswire | -2.44% | — | |
| Form 10-Q CervoMed Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -2.44% | — | |
| Form S-8 CervoMed Inc. | SEC filing · Form S-8 | SEC EDGAR | -2.44% | — | |
| CervoMed to Participate in Fireside Chat to Highlight Recent Progress in the Neflamapimod Clinical Development Program at the Canaccord Genuity 46th Annual Growth Conference | Press release | GlobeNewswire | -2.85% | +0.00% | |
| CervoMed Announces Neflamapimod Awarded Innovation Passport Designation Under the UK Innovative Licensing and Access Pathway (ILAP) for Treatment of Dementia with Lewy Bodies (DLB) | Press release | GlobeNewswire | +0.37% | +4.09% | |
| Form 8-K CervoMed Inc. For: Aug 04 | SEC filing · Form 8-K | SEC EDGAR | +0.37% | +4.09% | |
| CervoMed Announces New Clinical, Plasma Biomarker and Imaging Data at AAIC 2026 for Neflamapimod in the Treatment of Dementia with Lewy Bodies (DLB) | Press release | GlobeNewswire | -3.60% | -7.51% | |
| Form 8-K CervoMed Inc. For: Jul 14 | SEC filing · Form 8-K | SEC EDGAR | -7.79% | -4.36% | |
| Form EFFECT CervoMed Inc. | SEC filing · Form EFFECT | SEC EDGAR | -4.30% | -5.16% | |
| CervoMed Announces Completion of Enrollment in Phase 2 Study of Neflamapimod for Nonfluent Variant Primary Progressive Aphasia, a Type of Frontotemporal Dementia | Press release | GlobeNewswire | +0.00% | +9.04% | |
| Form 8-K CervoMed Inc. For: Jul 09 | SEC filing · Form 8-K | SEC EDGAR | +0.81% | -4.03% | |
| CervoMed Showcases Leadership in Advancing the Treatment and Care of Dementia with Lewy Bodies at the Alzheimer's Association International Conference (AAIC) 2026 | Press release | GlobeNewswire | -2.11% | +0.56% | |
| Form S-3 CervoMed Inc. | SEC filing · Form S-3 | SEC EDGAR | +0.00% | -2.29% | |
| CervoMed Announces Closing of $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules | Press release | GlobeNewswire | +2.02% | -6.30% | |
| Form 8-K CervoMed Inc. For: Jun 18 | SEC filing · Form 8-K | SEC EDGAR | -1.61% | +1.98% | |
| Form 8-K CervoMed Inc. For: Jun 22 | SEC filing · Form 8-K | SEC EDGAR | +2.02% | -6.30% | |
| CervoMed Announces $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules | Press release | GlobeNewswire | -3.95% | -37.92% | |
| CervoMed Secures New U.S. Patent Protecting Use of Neflamapimod in Pure Dementia with Lewy Body Patients into 2042 | Press release | GlobeNewswire | +10.30% | -9.98% | |
| Form 8-K CervoMed Inc. For: Jun 16 | SEC filing · Form 8-K | SEC EDGAR | +10.30% | -9.98% | |
| Form 8-K CervoMed Inc. For: Jun 15 | SEC filing · Form 8-K | SEC EDGAR | -4.48% | +34.92% | |
| CervoMed to Participate in the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit | Press release | GlobeNewswire | -2.41% | -1.61% | |
| CervoMed Announces Private Placement Financing and Plan to Focus on Strategic Partnering to Advance Neflamapimod into Phase 3 for Dementia with Lewy Bodies | Press release | GlobeNewswire | -13.32% | -17.88% | |
| Form 8-K CervoMed Inc. For: Jun 09 | SEC filing · Form 8-K | SEC EDGAR | -13.32% | -17.88% | |
| Form 8-K CervoMed Inc. For: Jun 08 | SEC filing · Form 8-K | SEC EDGAR | -3.70% | -2.37% | |
| CervoMed Reports First Quarter 2026 Financial Results and Provides Corporate Updates | Press release | GlobeNewswire | -1.64% | -9.25% | |
| Form 8-K CervoMed Inc. For: May 18 | SEC filing · Form 8-K | SEC EDGAR | -1.33% | -3.67% | |
| Form 10-Q CervoMed Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | -8.02% | |
| Form ARS CervoMed Inc. For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +0.00% | +0.27% | |
| Form DEF 14A CervoMed Inc. For: Jun 08 | SEC filing · Form DEF | SEC EDGAR | — | -0.21% | |
| CervoMed Announces New Data at the 2026 AAN Annual Meeting that Demonstrated Neflamapimod Increased Basal Forebrain Volume and Functional Connectivity in Dementia with Lewy Bodies | Press release | GlobeNewswire | +3.00% | -1.50% | |
| Form 8-K CervoMed Inc. For: Apr 22 | SEC filing · Form 8-K | SEC EDGAR | +2.27% | -2.78% | |
| CervoMed to Provide Neflamapimod Clinical Program Update and Participate in a Panel on Biomarkers at 2026 Lewy Body Dementia Association Annual Meeting | Press release | GlobeNewswire | — | -1.96% | |
| Form 8-K CervoMed Inc. For: Apr 07 | SEC filing · Form 8-K | SEC EDGAR | +3.97% | +3.59% | |
| Form 8-K CervoMed Inc. For: Mar 23 | SEC filing · Form 8-K | SEC EDGAR | -0.45% | -3.21% | |
| CervoMed Announces New Data at the AD/PD™ 2026 Scientific Conference that Reinforce Neflamapimod’s Positive Effects in Dementia with Lewy Bodies (DLB) in Patients without Alzheimer’s Disease Co-Pathology | Press release | GlobeNewswire | +2.84% | +0.00% | |
| Form 8-K CervoMed Inc. For: Mar 19 | SEC filing · Form 8-K | SEC EDGAR | -3.78% | -4.96% | |
| CervoMed Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Updates | Press release | GlobeNewswire | -3.92% | +4.38% | |
| Form 8-K CervoMed Inc. For: Mar 17 | SEC filing · Form 8-K | SEC EDGAR | -3.30% | -6.81% | |
| Form 10-K CervoMed Inc. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +2.34% | +0.94% | |
| CervoMed Announces Presentations at Upcoming AD/PD™ 2026 Scientific Conference | Press release | GlobeNewswire | +0.90% | -2.70% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the CRVO section they belong to.
Where else CRVO is measured.
CRVO earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is CervoMed Inc.'s median reaction calculated?
Every labeled CRVO news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 281 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 49% of CRVO's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does CRVO's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.